PD-L1

Modification of PLAC8 by UFM1 affects tumorous proliferation and immune response by impacting PD-L1 levels in triple-negative breast cancer
Misha Mao, Yongxia Chen, Jingjing Yang, Yifan Cheng, Ling Xu, Feiyang Ji, Jichun Zhou, Xun Zhang, Zhaoqing Li, Cong Chen, Siwei Ju, Jiahang Zhang, Linbo Wang

Journal for ImmunoTherapy of Cancer Dec 2022, 10 (12) e005668; DOI: 10.1136/jitc-2022-005668
PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way
Xiaolu Yu, Yiru Long, Binfan Chen, Yongliang Tong, Mengwen Shan, Xiaomin Jia, Chao Hu, Meng Liu, Ji Zhou, Feng Tang, Henglei Lu, Runqiu Chen, Pan Xu, Wei Huang, Jin Ren, Yakun Wan, Jianhua Sun, Jia Li, Guangyi Jin, Likun Gong

Journal for ImmunoTherapy of Cancer Oct 2022, 10 (10) e004590; DOI: 10.1136/jitc-2022-004590
Rational combinations of immunotherapeutics that target discrete pathways
Stefani Spranger, Thomas Gajewski

Journal for ImmunoTherapy of Cancer Dec 2013, 1 (1) 16; DOI: 10.1186/2051-1426-1-16
A nomogram-based immunoprofile predicts overall survival for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy
Jingjing Duan, Yongwei Xie, Lijuan Qu, Lingxiong Wang, Shunkai Zhou, Yu Wang, Zhongyi Fan, Shengsheng Yang, Shunchang Jiao

Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 100; DOI: 10.1186/s40425-018-0418-7
Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination
Jun Gong, Thang Q. Le, Erminia Massarelli, Andrew E. Hendifar, Richard Tuli

Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 46; DOI: 10.1186/s40425-018-0361-7
Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer
Jason M. Redman, Seth M. Steinberg, James L. Gulley

Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 91; DOI: 10.1186/s40425-018-0409-8
Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancy
Michael Lattanzi, Fang-Ming Deng, Luis A. Chiriboga, Alisa N. Femia, Shane A. Meehan, Gopa Iyer, Martin H. Voss, Yuliya Sundatova, William C. Huang, Arjun V. Balar

Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 97; DOI: 10.1186/s40425-018-0415-x
Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab
Nicolas A. Giraldo, Peter Nguyen, Elizabeth L. Engle, Genevieve J. Kaunitz, Tricia R. Cottrell, Sneha Berry, Benjamin Green, Abha Soni, Jonathan D. Cuda, Julie E. Stein, Joel C. Sunshine, Farah Succaria, Haiying Xu, Aleksandra Ogurtsova, Ludmila Danilova, Candice D. Church, Natalie J. Miller, Steve Fling, Lisa Lundgren, Nirasha Ramchurren, Jennifer H. Yearley, Evan J. Lipson, Mac Cheever, Robert A. Anders, Paul T. Nghiem, Suzanne L. Topalian, Janis M. Taube

Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 99; DOI: 10.1186/s40425-018-0404-0
Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy
Hao Liu, Zhen Zhao, Li Zhang, Yuanke Li, Akshay Jain, Ashutosh Barve, Wei Jin, Yanli Liu, John Fetse, Kun Cheng

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 270; DOI: 10.1186/s40425-019-0705-y
Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial
Ulka Vaishampayan, Patrick Schöffski, Alain Ravaud, Christian Borel, Julio Peguero, Jorge Chaves, John C. Morris, Nuria Kotecki, Martin Smakal, Dongli Zhou, Silke Guenther, Marcis Bajars, James L. Gulley

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 275; DOI: 10.1186/s40425-019-0746-2

Main menu

PD-L1

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

PD-L1

Pages